vasopharm

vasopharm GmbH is dedicated to the discovery and development of novel therapies for treating brain and cardiovascular diseases and their consequences. In this field, the company focuses on developing treatments that impact the bioavailability of nitric oxide (NO), a cell signaling molecule involved in numerous physiological and pathological processes. The candidate drug for vasculitis, vas203, is an allosteric nitric oxide synthase inhibitor, representing a completely new class of nitric oxide synthase (NOS) modulators. It rapidly reduces the excessive production of nitric oxide in cerebral blood vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.